Longitudinal changes in the intra-renal oxygenation by BOLD MRI in patients with

BOLD MRI 对患有以下疾病的患者肾内氧合的纵向变化

• 批准号: 8507728
• 负责人: POTTUMARTHI V PRASAD
• 金额: $ 43.81万
• 依托单位: NORTHSHORE UNIVERSITY HEALTHSYSTEM
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-10 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8507728
• 关键词: Accounting; Adult; Affect; Age; Animal Model; Biological Markers; Biopsy; Blood Vessels; Budgets; Categories; Chronic Kidney Failure; Creatinine; Data; Development; Diabetes Mellitus; Diagnosis; Dialysis procedure; Diffusion; Disease; Disease Progression; Early Diagnosis; End stage renal failure; Fibrosis; Foundations; Gelatinase A; Glomerular Filtration Rate; Human; Hypertension; Hypoxia; Image; Individual; Injury; Intervention; Iohexol; Kidney; Kidney Diseases; Kidney Transplantation; Lead; Length; Magnetic Resonance Imaging; Measurement; Medicare; Methods; Monitor; Patients; Perfusion; Physiological; Play; Population; Prevalence; Procedures; Process; Progressive Disease; Relative (related person); Renal Replacement Therapy; Renal function; Reproducibility; Rest; Risk; Risk Factors; Rodent; Role; Services; Spin Labels; Staging; Staging System; System; Testing; Ultrasonography; Work; base; blood oxygen level dependent; design; diabetic; drug development; drug testing; falls; follow-up; interest; novel; novel marker; post gamma-globulins; standard of care

DESCRIPTION (provided by applicant): The number of people affected by chronic kidney disease (CKD) is on the rise. This is partly attributed to the increasing number of diabetics and hypetensives. Currently it is estimated that over 15 million people have moderate CKD in the US. But only a fraction of these will progress and ultimately require transplantaion or dialysis services. Currently, there is not a good way of identifying subjects who will progress. Determining this has important implications in terms of patient management. So, there has recently been an increased interest in developing alternate markers to characterize CKD. We propose to test whether one or several MRI markers would be useful in identifying subjects at risk of progression. In this study, we will evaluate these measurements in a small number of subjects with moderate CKD. Three types of markers are being proposed, one is simple kidney size measurement. The second is to characterize the structural makeup of the kidney. Fibrosis is a consequence of CKD and is known to be a key determinant for the disease progression. We will use apparent diffusion coefficient measurement to evaluate the degree of fibrosis. It is also now becoming well accepted that kidneys become more hypoxic under diseased conditions and this actually may drive the processes responsible for development of fibrosis. We have pioneered in the use of BOLD MRI to evaluate intrarenal oxygenation and will test if it can identify subjects at risk of progression. We will also test arterial spin labeling method to evaluae relative renal perfusion. All the proposed methods do not require any exogenous contrast administration. If the project is successful, it may lead to one or more markers for identifying subjects at risk of progression and in turn may have a significant impact on patient management. Also, these markers could be useful in monitoring disease progression and interventions. This would be significant for drug development and testing novel interventional strategies both in animal models and in humans.

描述（由申请人提供）：受慢性肾脏病（CKD）影响的人数正在上升。这部分归因于糖尿病患者和高血压的数量增加。目前，据估计，在美国，超过1500万人的CKD中等。但是，其中只有一小部分会进展，最终需要移植或透析服务。当前，没有一个很好的方法来识别会进步的主题。确定这一点在患者管理方面具有重要意义。因此，最近人们对开发替代标记以表征CKD的兴趣增加了。我们建议测试一个或几个MRI标记对于识别有进展风险的受试者是否有用。在这项研究中，我们将在少数具有中等CKD的受试者中评估这些测量值。提出了三种标记，一种是简单的肾脏尺寸测量。第二个是表征肾脏的结构构成。纤维化是CKD的结果，已知是疾病进展的关键决定因素。我们将使用明显的扩散系数测量来评估纤维化程度。现在，在患病的情况下肾脏变得更加低氧也已被广泛接受，这实际上可能会驱动导致纤维化发展的过程。我们已经率先使用BOLD MRI来评估纳内氧合，并将测试它是否可以识别出进展风险的受试者。我们还将测试动脉自旋标记方法以评估相对肾脏灌注。所有提出的方法不需要任何外源对比度给药。如果该项目成功，它可能会导致一个或多个标记，以识别有进步风险的受试者，进而可能会对患者管理产生重大影响。同样，这些标记可能在监测疾病进展和干预措施中有用。这对于在动物模型和人类中的药物开发和测试新颖的介入策略都是重要的。